Key facts: Novartis' Scemblix gains CHMP backing; Kisqali shows 28% risk reduction
קריאה של פחות מדקה
- Novartis' Scemblix received a positive CHMP opinion for treating adults with newly diagnosed chronic myeloid leukemia. A European Commission decision is expected within two months.1
- Novartis reported a 5-year analysis from the Phase III Natalee trial of its drug Kisqali, showing a 28% reduction in the risk of recurrence among a broad early breast cancer patient population.2